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Abstract
Background
Chronic liver scarring from any cause leads to cirrhosis, portal hypertension, and a progres-
sive decline in renal blood flow and renal function. Extreme renal vasoconstriction character-
izes hepatorenal syndrome, a functional and potentially reversible form of acute kidney
injury in patients with advanced cirrhosis, but current therapy with systemic vasoconstrictors
is ineffective in a substantial proportion of patients and is limited by ischemic adverse
events. Serelaxin (recombinant human relaxin-2) is a peptide molecule with anti-fibrotic and
vasoprotective properties that binds to relaxin family peptide receptor-1 (RXFP1) and has
been shown to increase renal perfusion in healthy human volunteers. We hypothesized that
serelaxin could ameliorate renal vasoconstriction and renal dysfunction in patients with cir-
rhosis and portal hypertension.
Methods and findings
To establish preclinical proof of concept, we developed two independent rat models of cir-
rhosis that were characterized by progressive reduction in renal blood flow and glomerular
filtration rate and showed evidence of renal endothelial dysfunction. We then set out to fur-
ther explore and validate our hypothesis in a phase 2 randomized open-label parallel-group
study in male and female patients with alcohol-related cirrhosis and portal hypertension.
Forty patients were randomized 1:1 to treatment with serelaxin intravenous (i.v.) infusion
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and must follow the process outlined on the
(for 60 min at 80 μg/kg/d and then 60 min at 30 μg/kg/d) or terlipressin (single 2-mg i.v.
bolus), and the regional hemodynamic effects were quantified by phase contrast magnetic
resonance angiography at baseline and after 120 min. The primary endpoint was the
change from baseline in total renal artery blood flow.
Therapeutic targeting of renal vasoconstriction with serelaxin in the rat models increased
kidney perfusion, oxygenation, and function through reduction in renal vascular resistance,
reversal of endothelial dysfunction, and increased activation of the AKT/eNOS/NO signaling
pathway in the kidney. In the randomized clinical study, infusion of serelaxin for 120 min
increased total renal arterial blood flow by 65% (95% CI 40%, 95%; p < 0.001) from base-
line. Administration of serelaxin was safe and well tolerated, with no detrimental effect on
systemic blood pressure or hepatic perfusion. The clinical study’s main limitations were the
relatively small sample size and stable, well-compensated population.
Conclusions
Our mechanistic findings in rat models and exploratory study in human cirrhosis suggest the
therapeutic potential of selective renal vasodilation using serelaxin as a new treatment for
renal dysfunction in cirrhosis, although further validation in patients with more advanced cir-
rhosis and renal dysfunction is required.
Trial registration
ClinicalTrials.gov NCT01640964
Author summary
Why was this study done?
• Hepatorenal syndrome type 1 is a rapidly progressive, but potentially reversible, form of
acute kidney injury occurring in patients with liver cirrhosis, characterized by severe
renal vasoconstriction and a very poor prognosis. There is a significant unmet need for
a widely approved, safe, and effective pharmacological treatment.
• Serelaxin, a recombinant form of the human peptide hormone relaxin-2, has been
shown to increase renal perfusion in healthy human volunteers. We tested whether sere-
laxin could ameliorate renal vasoconstriction and renal dysfunction in cirrhosis.
What did the researchers do and find?
• Administration of serelaxin improved renal blood flow, oxygenation, and function in
two independent animal models of cirrhosis through reversal of endothelial dysfunction
and increased activation of nitric oxide signaling in the kidney.
• In an exploratory phase 2 clinical trial in patients with cirrhosis and portal hypertension,
serelaxin infusion induced a significant increase in renal blood flow and was safe and
well tolerated, with no adverse effects on systemic blood pressure or hepatic perfusion.
Serelaxin for renal dysfunction in cirrhosis
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What do these findings mean?
• Our data indicate that selective targeting of renal vasoconstriction using serelaxin may
modulate renal dysfunction in cirrhosis without affecting systemic blood pressure.
• Further studies in patients with more advanced cirrhosis and renal dysfunction are
required to confirm whether there are beneficial effects on renal function and patient
outcomes.
Introduction
Acute kidney injury (AKI) is a major challenge for healthcare providers and clinicians world-
wide, affecting an estimated 13 million people and contributing to 1.7 million deaths every
year [1]. AKI occurs in approximately 20% of patients with liver cirrhosis who are admitted
into hospital, and the associated morbidity and mortality remain unacceptably high [2]. Hepa-
torenal syndrome (HRS), the most severe form of AKI in cirrhosis, develops in more than 50%
of patients with cirrhosis who die [3]. HRS is a functional, and potentially reversible, type of
renal failure characterized by intense renal vasoconstriction and hypoperfusion and is associ-
ated with a dismal prognosis [4]. It occurs in response to portal hypertension (PHT) and the
associated splanchnic arterial vasodilatation and impairment of cardiac function that lead to a
reduction in effective circulating volume, with compensatory activation of neurohormonal
systems and an intrarenal imbalance between vasoconstrictor and vasodilator systems causing
increased renal vascular resistance (RVR) [5,6]. Pooling of blood in the splanchnic circulation
also alters gut permeability and enhances bacterial translocation, with the release of endotoxin
and increase in pro-inflammatory cytokines leading to amplification of circulatory dysfunc-
tion [7]. Imaging studies have shown a significant (~40%) reduction in renal blood flow (RBF)
and redistribution of intrarenal blood flow in patients with compensated cirrhosis compared
to healthy volunteers [8,9]. As cirrhosis advances, systemic hemodynamics are increasingly
disturbed, RBF becomes progressively compromised, and patients are susceptible to episodes
of AKI (including HRS) in response to precipitating factors, particularly bacterial infections
[10].
The median survival time for patients with the acute form of HRS (“type 1”) is only 4 wk,
highlighting the need for an effective pharmacological treatment [11]. Evidence also suggests
that even relatively mild cases of AKI, insufficient to make a diagnosis of HRS, have a negative
impact on patient survival, indicating that prompt and successful treatment of these episodes
could lead to improved clinical outcomes [12]. The most effective pharmacological treatment
for HRS type 1 is terlipressin (a splanchnic and systemic vasoconstrictor). However, in a recent
large randomized placebo-controlled trial, confirmed HRS reversal occurred in only 19.6% of
patients receiving terlipressin, and the drug was permanently discontinued in 20.4% due to
adverse (mainly ischemic) events [13]. An ideal treatment for HRS would consist of a drug
with selective vasodilator activity in the renal circulation but without significant vasodilator
effects in other vascular beds, particularly the splanchnic circulation.
The endogenous peptide hormone relaxin (RLX) regulates maternal hemodynamic adapta-
tions in early pregnancy through direct actions on the renal and systemic vasculature, in-
cluding reduced RVR, increased RBF, and increased glomerular filtration rate (GFR) [14].
Serelaxin for renal dysfunction in cirrhosis
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physiological salt solution; RBF, renal blood flow;
RVR, renal vascular resistance; s.c., subcutaneous;
SAE, serious adverse event; SD, standard
deviation; SEM, standard error of the mean; SMA,
superior mesenteric artery; SNP, sodium
nitroprusside.
Serelaxin (recombinant human relaxin-2) binds with high affinity to the G-protein-coupled
receptor RXFP1, which is differentially expressed in the renal and systemic vasculature [15]
and mediates vasoactive effects through a number of mechanisms including enhanced nitric
oxide (NO) signaling and antagonism of the vasoconstrictive effects of angiotensin-II and
endothelin [14]. However, in contrast to vasodilators such as nitroglycerin, which primarily
act via direct venodilation, the vasorelaxatory action of serelaxin in rats is thought to predomi-
nantly affect arteries [16]. We recently showed that administration of serelaxin in cirrhotic rats
decreased PHT through augmentation of hepatic NO signaling and a reduction in intrahepatic
vascular resistance [17]. In healthy human volunteers, intravenous infusion of serelaxin for 30
min increased RBF by 47% compared with baseline levels, irrespective of sex [18].
We hypothesized that serelaxin could ameliorate renal vasoconstriction and renal dys-
function in cirrhosis. To test our hypothesis, we first evaluated the effects of serelaxin in two
independent experimental rat models of cirrhosis that were characterized by a progressive
reduction in RBF and GFR and showed evidence of renal endothelial dysfunction. We then
determined the translational relevance of these findings in an exploratory phase 2 clinical trial
in patients with compensated cirrhosis and PHT who were randomized to treatment with sere-
laxin or terlipressin, followed by noninvasive hemodynamic assessments using magnetic reso-
nance imaging (MRI).
Methods
Experimental design
Our main objective was to use experimental and human models to establish proof of concept
for serelaxin in modulating renal vasoconstriction and thereby its potential as a novel clinical
therapy for renal dysfunction in cirrhosis.
Animal experiments were designed and implemented according to NC3Rs ARRIVE guide-
lines. We calculated sample sizes prospectively for the animal model experiments using our
previously published data (group means and standard deviations) on using serelaxin in rat cir-
rhosis induced by carbon tetrachloride (CCl4) and bile duct ligation (BDL) [17]. A sample size
of5 rats per group was computed using GPower version 3.1.2 [19] given α = 0.05, power
(1 − β) = 0.9, and effect size (d) = 2.64. Cage-mates were randomized to serelaxin or vehicle
treatment, and all surviving rats at designated endpoints were included in the data analysis. No
animals or potential outliers were excluded from the datasets presented. Biochemical and his-
tological assessments were performed in a blinded manner.
In addition, a phase 2 randomized clinical trial (ClinicalTrials.gov NCT01640964) was con-
ducted. The main purpose of this study was to investigate the hemodynamic effects of serelaxin
infusion on the renal and hepatic circulation, measured by phase contrast magnetic resonance
angiography (PC-MRA), in patients with compensated alcohol-related cirrhosis and PHT.
Terlipressin, a well-characterized drug licensed in many countries for treatment of variceal
bleeding and HRS, was used as a positive control to validate the sensitivity and dynamic range
of the PC-MRA methodology in this population. The study was not sized based on the power
to detect a difference between the serelaxin and terlipressin groups. Instead, a sample size of 20
patients per group was calculated to be sufficient to create a 90% confidence interval (CI) on
the mean change from baseline for all blood flow parameters that would exclude zero if a 25%
change was observed.
Ethics statement
Procedures involving animals were conducted with approval from the University of Edinburgh
Animal Welfare and Ethical Review Body and UK Home Office, and in compliance with the
Serelaxin for renal dysfunction in cirrhosis
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Animals (Scientific Procedures) Act 1986. Wherever possible, inhalational anesthesia was used
to maximize control of depth/duration of anesthesia. Animals were killed by an approved
Schedule 1 method by appropriately trained personnel. Human tissues were analyzed to vali-
date preclinical observations in accordance with the Human Tissue (Scotland) Act 2006. The
clinical trial was conducted according to the ethical principles of the Declaration of Helsinki
2013 and following approval from the Scotland A Research Ethics Committee (REC Ref: 12/
SS/0177). All patients gave written informed consent.
Rat carbon tetrachloride and bile duct ligation models
Animals were housed under standard conditions (12:12 h light-dark cycle, temperature
23 ± 2˚C), three rats per cage, and were acclimatized to the room for 1 wk before the beginning
of the experiments. Cirrhosis and PHT were induced in 8-wk (250–300 g) male wild-type
Sprague-Dawley rats by intraperitoneal CCl4 (Sigma-Aldrich) treatment for up to 16 wk or by
BDL for up to 4 wk, as described previously [17]. Cage-mates were randomly allocated to CCl4
versus olive oil (OO) vehicle treatment or to BDL versus sham procedure (where the common
bile duct was exposed but not ligated).
Sustained (72 h) serelaxin hemodynamic study
Both 16-wk CCl4 (n = 16) and 3-wk post-BDL (n = 14) rats were randomized to receive contin-
uous treatment for 72 h with serelaxin (4 μg/h) or vehicle via subcutaneous (s.c.) osmotic mini-
pumps (2ML1 Alzet, Durect). Groups of CCl4 rats (n = 12) were also randomized to serelaxin
or vehicle plus coadministration of L-NG-nitroarginine methyl ester (L-NAME) (Sigma-
Aldrich) 250 mg/ml in drinking water, starting 24 h before osmotic minipump insertion and
continuing for the 72-h study period. After 72 h, rats had hemodynamic and renal functional
measurements performed under terminal isoflurane anesthesia, as detailed below.
Acute serelaxin hemodynamic study
Serelaxin was supplied under material transfer agreement by Corthera (a Novartis affiliate
company). Groups of OO control rats (n = 12) or 16-wk CCl4 rats (n = 14) were randomized
to injection of serelaxin (4 μg in 200 μl intravenous [i.v.]) or an equivalent volume of vehicle,
and anesthetized for continuous hemodynamic monitoring over 60 min.
Acute nitrovasodilator hemodynamic study
Groups of 16-wk CCl4 rats (n = 6) were anesthetized and treated with a range of doses of
sodium nitroprusside (SNP; 0.09, 0.9, and 9 μg in 200 μl i.v.; Sigma-Aldrich) or an equivalent
volume of vehicle. Continuous hemodynamic monitoring was undertaken for 10 min after
each dose, as described above.
Hemodynamic measurements
Hemodynamic monitoring was performed using aseptic technique in rats anesthetized with
Inactin (Sigma-Aldrich) 0.1 ml/100 g (125 mg/ml) unless otherwise specified. Briefly, a trache-
ostomy was created, the right internal jugular vein cannulated with PE50 tubing (Smiths Medi-
cal), and 0.9% NaCl instilled at 0.05 ml/100 g/min throughout surgery and then 0.03 ml/100 g/
min during stabilization/monitoring. Rats received 5% inulin-FITC (Sigma-Aldrich) in 0.9%
NaCl for GFR measurement. Body temperature was maintained at 37˚C using a heat mat.
Mean arterial pressure (MAP) and heart rate (HR) were measured via a right femoral artery
PE50 catheter, portal pressure (PP) using a 24G cannula inserted into the portal vein, and RBF
Serelaxin for renal dysfunction in cirrhosis
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using a Doppler transit time probe (MA2PSB, ADInstruments) placed around the left renal
artery proximal to the bifurcation, all connected to a Powerlab 4/35 system and analyzed using
LabChart 7 Pro software (ADInstruments). Rats were stabilized for 20 min prior to data
recording. The urinary bladder was catheterized with PE90 tubing. At the end of the experi-
ment, blood was collected and tissues fixed in 10% buffered formalin or snap frozen.
Glomerular filtration rate measurement
A continuous infusion of 5% inulin-FITC in 0.9% NaCl was instilled at 0.03 ml/100 g/min.
Two 20-min urine collections were performed after 20 min of stabilization, and plasma sam-
ples were collected at baseline, 20 min, and 40 min for each rat and frozen immediately on dry
ice. Samples were thawed and spun down before analysis. Urine was diluted 1:100 in HEPES
buffer (HEPES 1.19 g, 450 ml of distilled water, pH adjusted to 7.4 with 5 M NaOH, and auto-
claved). A nine-point 2-fold dilution series was constructed starting with 1 mg/ml in HEPES
buffer (20 μl in 980 μl of buffer). All samples were further diluted 1:100 in HEPES buffer and
were analyzed in duplicate. Then, 190 μl was loaded per well, and fluorescence read at 485 nm
(excitation) and 538 nm (emission). Concentrations of inulin were calculated from the stan-
dard curve. The urine volume and urine and plasma concentrations of inulin were measured.
The GFR was calculated as follows: [(urine inulin × urine volume/min)/plasma inulin]. The
mean plasma inulin concentration was 0.18 mg/ml.
Wire myography
Wire myography was performed using isolated renal vessels as described previously [20]. Vas-
cular responses were studied in vessels from 16-wk OO/CCl4 rats (n = 6) using physiological
inhibitors of NO, cyclooxygenase, and endothelium-derived hyperpolarizing factor (EDHF)
signaling, and in groups of 4-wk sham/BDL rats and 16-wk OO/CCl4 rats after 72-h serelaxin
or vehicle infusion (n = 6/8 per group). Harvested vessels (extrarenal and intrarenal renal
arteries) were placed in 4˚C physiological salt solution (PSS) (119 mM NaCl, 4.7 mM KCl, 2.5
mM CaCl2, 1.17 mM MgSO4, 25 mM NaHCO3, 1.18 mM KH2PO4, 0.026 mM K2EDTA, and
5.5 mM D-glucose). Extrarenal, segmental, and interlobar renal arteries were dissected and
cleaned of connective tissue. Rings of 2 mm were mounted from each vessel segment onto
40-mm stainless steel wires, one end of which was attached to a force transducer, and the other
to a micrometer. The vessel ring was bathed in PSS at 37˚C and bubbled with 95% O2 and 5%
CO2, and stepwise radial stretching was performed to determine the lumen diameter necessary
for optimal force generation. Vessel rings were then stretched to achieve 90% of the diameter
expected if they had been fully relaxed and exposed to a transmural pressure of 13.3 kPa (100
mm Hg). The vessel ring was allowed to equilibrate for 30 min before viability was assessed
using three stimulations with KPSS (125 mM K, equimolar substitution of NaCl with KCl in
PSS), then activation for 2 min with each solution, followed by a 5-min washout period in PSS
to allow full relaxation. Measurement of viability was performed in these vessels to confirm
that isolation and mounting of the vessel did not damage the arterial wall. The ability of the
vessel to respond to contractile and dilator agents was investigated by producing concentra-
tion–response curves (CRCs). CRCs were obtained for phenylephrine (1 × 10−9 to 3 × 10−5 M;
Sigma-Aldrich), and a concentration that produced 80% maximum contraction (EC80) was
chosen for each individual rat vessel ring. Following contraction, CRCs were obtained to
the endothelium-dependent vasodilator acetylcholine (ACh; 1 × 10−9 to 3 × 10−5 M; Sigma-
Aldrich) and the endothelium-independent vasodilator SNP (1 × 10−9 to 3 × 10−5 M; Sigma-
Aldrich). To determine the mechanism underlying physiological endothelium-dependent
vasodilatation in isolated normal/control rat renal arteries, vessels were pretreated with either
Serelaxin for renal dysfunction in cirrhosis
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the NO synthase (NOS) inhibitor L-NAME (1 × 10−4 M; Sigma-Aldrich), the cyclooxygenase
(COX) inhibitor indomethacin (1 × 10−5 M; Sigma-Aldrich), or the endothelium-derived
hyperpolarizing factor inhibitors apamin (1 × 10−4 M; Sigma-Aldrich) and charybdotoxin
(1 × 10−5 M; Sigma-Aldrich) before stimulation with ACh.
Kidney blood-oxygen-level-dependent magnetic resonance imaging
studies
Groups of 8-wk (n = 16) and 16-wk CCl4-treated rats (n = 12) were randomized to serelaxin
(4 μg in 200 μl i.v.) or vehicle (200 μl), and kidney blood-oxygen-level-dependent MRI (BOLD-
MRI) measurements (T2) were acquired using a 7.0 Tesla preclinical MRI scanner (Agilent
Technologies).
Animals were anesthetized with isoflurane, and the tail vein was cannulated for serelaxin or
vehicle injection. Core body temperature was maintained at 37˚C, and respiratory rate was
recorded throughout the scanning protocol. A birdcage volume coil (72-mm diameter) and a
four-channel phased array surface coil (Rapid Biomedical) were used for radio frequency
transmission and signal reception, respectively. BOLD-MRI image acquisition used a multie-
cho gradient-recalled echo pulse sequence of ten T2 weighted images; TE = 4, 8, 12, 16, 20,
24, 28, 32, 36, and 40 ms; TR = 100 ms; and flip angle of 30˚. An axial slice through the center
of the right kidney was selected with 50 × 40 mm field of view containing a 192 × 128 acquisi-
tion matrix (in-plane resolution = 0.26 × 0.31 mm). Selecting a single axial slice aligned parallel
with the renal artery, identified by rapid scout scanning (fast gradient echo, three slices in cor-
onal orientation), ensured that the slice position encompassed the most representative section
of the kidney regions. Slice thickness was 2 mm, with 14 signal averages. The scan time was 3
min for each BOLD-MRI scan.
High-resolution ultrasound studies
Groups of 16-wk CCl4 rats (n = 16) were randomized to serelaxin (4 μg in 200 μl i.v.) or vehicle
(200 μl), and RBF and cardiac output (CO) were assessed by ultrasound (Vevo 770, VisualSonics).
Animals were anesthetized with isoflurane, placed in a supine position on a heated table
(VisualSonics, Fujifilm), and cannulated via tail vein for injection of serelaxin or vehicle. Heart
rate was monitored continuously using an electrocardiogram, and core body temperature was
maintained at 37˚C using the heated table and a heat lamp as required. The chest and abdomi-
nal regions were shaved and remaining hair removed with depilatory cream. Parasternal, long-
axis B-mode and M-mode images were taken of the heart at the level of the papillary muscle
for quantitative assessment of cardiac function at baseline and at 60 min after injection of sere-
laxin or vehicle. Measurements included end systolic and end diastolic left ventricular area
and volume, stroke volume, CO, and ejection fraction. A short-axis image of the right kidney
was then obtained, and, using pulse-wave Doppler, measurements of RBF were taken from the
superior branch of the renal artery distal to the point of renal artery bifurcation at the hilum.
Measurement of renal artery Doppler ultrasound parameters (peak velocity, velocity time inte-
gral, and Pourcelot resistive index [(peak systolic velocity − end diastolic velocity)/peak systolic
velocity]) were taken at baseline and every 10 min for 60 min.
Immunofluorescence
Kidney tissue sections (7 μm) were incubated with primary anti-RXFP1 (H-160) antibody
(Santa Cruz Biotechnology, sc-50328; 1:200 rat, 1:500 human) and detected with ImmPRESS
HRP Anti-Rabbit IgG (Vector Laboratories, MP-7401). The HRP label was amplified with
Cy3-conjugated tyramine (PerkinElmer, SAT704B001EA).
Serelaxin for renal dysfunction in cirrhosis
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Determination of hepatic collagen proportionate area
Liver tissue sections (3 μm) from four separate lobes were stained with picrosirius red, and col-
lagen proportionate area (percent) calculated as described previously [17].
Quantification of renal acute tubular necrosis
Hematoxylin-and-eosin-stained kidney sections were assessed for acute tubular necrosis
(ATN) by a histopathologist blinded to treatment allocation. Ten high-power fields (×400)
were analyzed for the percentage of tubules showing cell necrosis, loss of brush border, cast
formation, and tubule dilatation and scored as follows: 0, none; 1,10%; 2, 11%–25%; 3, 26%–
45%; 4, 46%–75%; and 5,>76%.
Reverse transcription and real-time PCR
RNA extraction, reverse transcription, and real-time PCR were performed as described previ-
ously [17] using validated primer/probe sets for rat RXFP1 (Rn01495351_m1) and eukaryotic
18S (Applied Biosystems) or the Rat Hypertension RT2 Profiler PCR Array (Qiagen). Gene
expression was normalized to 18S rRNA, and relative expression calculated by 2−ΔΔCt method.
Human relaxin-2 and TNFαmeasurement
Rat serum was diluted 1:4 before human relaxin-2 or TNFα levels were determined using
solid-phase Quantikine ELISA (R&D Systems).
Nitric oxide synthase assay
Whole kidney tissue was homogenized in phosphate-buffered saline (pH 7.4) and centrifuged
at 10,000g for 10 min, and supernatant collected. Then, 150 μg of protein was used to measure
NOS activity using an EnzyChrom kit (BioAssay Systems).
Nitric oxide measurement
Rat serum was centrifuged (13,000g, 2 min) before filtration using a 10,000-Da molecular
weight cutoff filter (Millipore). NO/NO3
−/NO2 determination was performed using the
Parameter Total Nitric Oxide and Nitrate/Nitrite Assay Kit (R&D Systems).
Western blotting
Western blotting was performed as described previously [17] using the following primary anti-
bodies/dilutions: panAKT, 1:1,000; phospho-AKTThr308, 1:1,000; eNOS, 1:1,000; phospho-
eNOSSer117, 1:1,000 (all Cell Signaling Technology); relaxin receptor 1 H160, 1:1,000 (Santa
Cruz Biotechnology). Densitometry was performed using ImageJ software (US National Insti-
tutes of Health).
Clinical trial
We undertook a randomized open-label non-controlled parallel-group exploratory phase 2
clinical trial in n = 40 patients recruited at the Royal Infirmary of Edinburgh (Edinburgh, UK)
between April 2013 and October 2014 (Protocol: CRLX030X2201, version 01; see S1 Text).
Inclusion/exclusion criteria. The following inclusion criteria applied: age 18–75 y, male
or female, and cirrhosis of alcohol etiology with clinical and/or endoscopic evidence of PHT.
Key exclusion criteria included the following: use or plan for use of any drug to treat PHT (e.g.,
nonselective beta blockers), decompensated cirrhosis (Child-Pugh score> 9 at screening) and/
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or ascites and/or hepatic encephalopathy, variceal bleed in the preceding month, ongoing drug
or alcohol abuse, severe renal impairment (estimated GFR< 30 ml/min), systolic blood
pressure< 110 mm Hg, hepatocellular carcinoma, known portal or splenic vein thrombosis,
prolonged corrected QT interval, contraindication to MRI scan, contraindication to terlipressin,
and any uncontrolled clinically significant disease.
Interventions. After written informed consent was obtained, patients underwent three
study visits: screening, treatment, and follow-up at −7, 0, and 29 d, respectively. Eligible
patients were randomly assigned (1:1) to treatment with either (1) i.v. infusion of serelaxin at
an initial rate of 80 μg/kg/d (equivalent to 3.33 μg/kg/h) for the first 60 min, followed by a sub-
sequent rate of 30 μg/kg/d (equivalent to 1.25 μg/kg/h) for the next 60 min or (2) a single i.v.
bolus of 2 mg of terlipressin acetate. Participants were monitored for 120 min after the initia-
tion of treatment. We used a pragmatic 120-min time frame as pharmacokinetic studies had
indicated that steady-state serum serelaxin levels efficacious in a phase 3 acute heart failure
trial could be achieved within this period [21] and the marked hemodynamic effects of i.v. ter-
lipressin persist for up to 4 h [22]. The study had a 4-wk follow-up time point because this was
considered the best interval for detecting anti-serelaxin antibody development.
Randomization. Participants were randomized using computer-generated allocation
cards. The patient randomization list was produced by Novartis Drug Supply Management
using a validated automated system. The randomization scheme was reviewed and approved
by a member of the Novartis Biostatistics Quality Assurance Group.
Outcome measures. The primary outcome was the change from baseline in the total renal
artery blood flow following serelaxin treatment (where the flow is the average flow over the
cardiac cycle, and total renal artery flow = left + right renal artery flow measured by PC-
MRA). Secondary outcomes were as follows: the change from baseline in total renal artery
flow 120 min after terlipressin treatment; the change in blood flow from baseline following ser-
elaxin treatment in the portal vein, hepatic artery, superior mesenteric artery (SMA), and supe-
rior abdominal aorta (above renal bifurcation); and the number of patients with adverse events
(AEs), serious adverse events (SAEs), and death, as assessment of safety and tolerability of sere-
laxin over the 4-wk study period. Prespecified exploratory outcomes included the change in
blood flow from baseline following serelaxin treatment in the inferior abdominal aorta (below
renal bifurcation) and the azygos vein, and the effects of serelaxin treatment on selected bio-
markers, pharmacokinetics, and immunogenicity.
Study assessments. For PC-MRA, a 3.0 Tesla whole body MRI scanner using the Verio
platform (Siemens Healthcare) equipped with spine and body receiver array coils was used to
acquire ECG-gated noncontrast magnetic resonance angiography using 3-D gradient echo
(FLASH) sequences and 2-D true fast imaging with steady-state precession (FISP) for localiza-
tion of the hepatorenal vasculature. The phase images from the 3-D PC-MRA sequences were
analyzed before and after serelaxin or terlipressin treatment (S10 Fig). Outcome assessors for
PC-MRA were blinded to treatment allocation. For each vessel, the velocity encoding of the
acquisition was adjusted on a patient-by-patient basis. All images were checked visually after
each flow measurement sequence; if motion artifacts were detected, the individual vessel scan
was repeated. Flow measurements were derived from a semi-automated analysis of phase con-
trast images using Siemens Argus Flow software. On the vascular images where the PC-MRA
phase sequence had been applied, contours were drawn manually (or semi-automatically after
seed points were indicated at the lumen boundary) at end diastole (first image of the cine
acquisition) and end systole (smallest cavity size during cardiac cycle) on every slice. For the
flow measurements, the lumen of each vessel was carefully evaluated at the peak systolic phase
image, and the area of the lumen was used as the region of interest for the flow and velocity
quantification program (S11 Fig), yielding values that represent average volumetric flow rate
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and peak systolic velocity within the vessel [23]. The same magnetic resonance angiography
scans were submitted to an imaging clinical research organization (Bioclinica) for archiving
and for performing an additional exploratory analysis to compare the performance of another
software platform that utilizes a fully automated image analysis algorithm. The RBF values and
change from baseline data were highly correlated for both the serelaxin and terlipressin arms
in comparison to the semi-automated approach. The use of an automated approach reduces
reader bias and provides a platform to scale to evaluation of multicenter imaging data.
Biomarkers. All biomarker samples from the same patient were analyzed in the same
batch by laboratory personnel at the central laboratory (Quintiles, UK) using commercially
available assay kits. Ethylenediaminetetraacetic acid (EDTA) plasma nitrate levels were mea-
sured using the R&D Systems Parameter Total Nitric Oxide and Nitrate/Nitrite Assay. EDTA
plasma endothelin-1 levels were measured using the Biomedica Endothelin ELISA. Lithium
heparin plasma MMP-9 levels were measured using the R&D Systems Quantikine ELISA
Human MMP-9 Immunoassay.
Blood samples from serelaxin-treated patients were collected for pharmacokinetics
(relaxin-2 ELISA; R&D Systems) and immunogenicity analysis (anti-serelaxin antibody detec-
tion in a validated four-tiered assay approach) by Laboratory of the Government Chemist.
Safety assessments. Safety assessments consisted of collecting all data on AEs, SAEs,
deaths, AE severity and relationship to study drug, and pregnancies. Monitoring of hematol-
ogy and clinical chemistry were performed at a central laboratory, and assessments of vital
signs and physical condition were performed regularly. ECGs were done locally at screening,
and centrally read ECGs were done at four time points at visit 2 and sent electronically to a
designated clinical research organization (ERT).
Statistical analysis
Primary data from preclinical experiments are expressed as mean ± standard error of the
mean (SEM), mean differences between groups, and 95% CIs. Differences among groups were
assessed with one-way analysis of variance (ANOVA), two-way ANOVA, or repeated mea-
sures ANOVA with a Bonferroni correction, and between pairs with an unpaired two-tailed
Student’s t-test. CRCs from myography were fitted to a sigmoidal curve using nonlinear
regression. For the clinical trial, summary statistics for continuous variables were calculated
(n, mean, standard deviation [SD], median, quartiles, minimum, maximum, geometric mean,
and 95% CI on the geometric mean). Summary statistics for the baseline, post-baseline, and
change from baseline measurements of blood flow for patients in the serelaxin group are pre-
sented for each time point. CIs were also constructed on the change from baseline parameters
and were calculated for both the arithmetic and geometric means. A paired two-tailed Stu-
dent’s t-test was used to compare baseline and post-baseline parameters. Data for the terlipres-
sin group were analyzed in a similar manner as for the serelaxin group. GraphPad Prism
version 5.03 (GraphPad Software) was used to perform statistical calculations. p< 0.05 was
considered statistically significant.
Results
Rat models of cirrhosis and portal hypertension exhibited renal
vasoconstriction and renal functional impairment
CCl4-treated rats developed cirrhosis and PHT (Figs 1A and S1A) but no jaundice or signifi-
cant ascites. After 16 wk, there was a marked reduction in RBF (CCl4 2.4 ± 0.2 ml/min versus
OO 7.3 ± 1.0 ml/min; mean difference d = −4.84, 95% CI −7.69, −1.99; p< 0.001) and GFR
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(CCl4 0.8 ± 0.2 ml/min versus OO 2.4 ± 0.4 ml/min; d = −1.65, 95% CI −2.82 −0.48; p = 0.005)
(Fig 1B and 1C). Urinary sodium levels showed a nonsignificant reduction in 16-wk CCl4 rats
(CCl4 34 mmol/l versus OO 55 mmol/l; p = 0.22), consistent with the sodium-retaining pheno-
type associated with this model [24]. Despite significant renal functional impairment, kidney
histology in CCl4-treated animals showed only minor tubular injury (Fig 1D).
In contrast, following BDL, rats were jaundiced after 2 wk, and all had moderate to severe
ascites after 4 wk. Liver histology showed florid inflammation, collagen accumulation, and
architectural distortion (S1F Fig). The PP increased progressively after BDL (Fig 1E), whereas
Fig 1. Rat models of advanced cirrhosis, portal hypertension, and renal dysfunction. Portal pressure
(PP; A), renal blood flow (RBF; B), and glomerular filtration rate (GFR; C) in 16-wk CCl4 and olive oil (OO)
control rats (n = 6–11). Representative H&E-stained kidney (scale bar 50 μm) showing minor tubular epithelial
cell vacuolation (arrows) without significant necrosis after 16 wk of CCl4 (D). PP (E), RBF (F), and GFR (G) in
bile duct ligation (BDL) and sham-operated (sham) control rats (n = 4–8). Representative H&E-stained kidney
(scale bar 50 μm) showing necrotic cells within the tubule lumen and loss of the normal circumferential
epithelial cell population (arrows) 4 wk after BDL (H). Data presented as mean ± standard error of the mean,
analyzed by one-way ANOVA with post hoc Bonferroni correction (*p < 0.05; **p < 0.01; ***p < 0.001).
doi:10.1371/journal.pmed.1002248.g001
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there was a substantial decrease in RBF (4-wk BDL 1.5 ± 0.4 ml/min versus sham 6.5 ± 1.5 ml/
min; d = −4.97, 95% CI −8.48, −1.47; p = 0.0037) (Fig 1F) and GFR (4-wk BDL 0.7 ± 0.3 ml/
min versus sham 2.4 ± 0.2 ml/min; d = −1.74, 95% CI −2.92, −0.55; p = 0.0023) (Fig 1G). Uri-
nary sodium was variable in BDL rats, though 4-wk BDL levels were in line with published
data [21] (4-wk BDL 46 mmol/l versus sham 58 mmol/l; p = 0.73). Kidney histology in BDL
animals showed features of ATN (Fig 1H).
Impaired renal arterial vascular responses and the role of nitric oxide
Extrarenal renal arteries harvested from 16-wk CCl4 and 4-wk BDL rats showed a markedly
attenuated response to the endothelium-dependent vasodilator ACh (Fig 2A and 2E). The
Fig 2. Vascular responses in isolated extrarenal renal arteries from cirrhotic rats. Concentration–
response curves to acetylcholine (ACh; A and E), phenylephrine (PE; B and F), and sodium nitroprusside
(SNP; C and G) in isolated extrarenal renal arteries from 16-wk CCl4 and 4-wk bile duct ligation (BDL) rats (n =
8–12). Data presented as mean ± standard error of the mean (SEM), relative to preconstricted value, analyzed
by two-way ANOVA with post hoc Bonferroni correction (*p < 0.05; ***p < 0.001; NS, not significant). Nitric
oxide synthase (NOS) activity in whole kidney extracts from 16-wk CCl4 (D) and 4-wk BDL (H) rats (n = 6–7).
Data presented as mean ± SEM, analyzed by unpaired t-test (*p < 0.05). OO, olive oil.
doi:10.1371/journal.pmed.1002248.g002
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−logIC50 (the −log of the concentration of ACh needed to reduce contraction by 50%) was
lower in vessels from cirrhotic rats compared to controls (CCl4 6.42 ± 0.14 versus OO 6.88 ±
0.11, p< 0.001; BDL 6.29 ± 0.12 versus sham 6.52 ± 0.05, p< 0.001), caused by a rightward
shift in the CRC. The Emax to ACh (percent of maximal dilatation achieved) was lower in ves-
sels from cirrhotic rats compared to controls (CCl4 47.99% ± 8.57% versus OO 78.61% ±
5.17%, p = 0.0056; BDL 51.33% ± 11.76% versus sham 72.84% ± 5.86%, p = 0.13). Significant
impairment of endothelium-dependent vasodilation was also observed at the level of the
smaller (segmental and interlobar) intrarenal arteries in both cirrhosis models (S2A–S2D Fig).
NOS was shown to be critical to endothelium-dependent renal arterial vasodilation in both
normal and cirrhotic rats (S2E and S2F Fig). There were no differences in response to the vaso-
constrictor phenylephrine or endothelium-independent vasodilator SNP in either model (Fig
2B, 2C, 2F and 2G).
Nitric oxide synthase activity was reduced in kidneys from cirrhotic rats
There was a substantial reduction in renal NOS activity (Fig 2D and 2H) and phosphorylated
eNOS (p-eNOS) protein (S3A and S3B Fig) in cirrhotic rats. Additionally, there was increased
transcription in kidney of genes involved in the regulation of vascular tone (endothelin recep-
tor A [Ednra] and B [Ednrb] and arginine vasopressin receptor 1a [Agtr1a]) and negative regu-
lators of NOS activity (arginase-II [Arg2] and caveolin-I [Cav1]) (S3C and S3D Fig). Increased
arginase-II and caveolin-I protein was also shown (S3E–S3H Fig).
RXFP1 expression was upregulated in kidney and localized to the renal
vasculature in rat cirrhosis models
Rxfp1 transcript levels were markedly increased in 16-wk CCl4 and 4-wk BDL rat kidneys com-
pared to controls (CCl4: d = 4.2, 95% CI 1.77, 6.71, p = 0.0042; BDL: d = 18, 95% CI 11.15,
24.84, p< 0.001) (Fig 3A and 3E). Relative RXFP1 protein levels were also increased in 16-wk
CCl4 and, to a lesser extent, 4-wk BDL rat kidneys (S4B and S4D Fig). RXFP1 staining localized
to renal vascular endothelium and smooth muscle, as well as perivascular adventitial cells (S4E
Fig). Kidney biopsies are not routinely performed for the clinical diagnosis of HRS, but a simi-
lar staining pattern for RXFP1 was observed in normal human kidney tissue (S4F Fig).
Sustained serelaxin infusion increased renal perfusion and reversed
renal dysfunction in advanced CCl4 cirrhotic rats
Mean serum serelaxin levels were 10.2 ± 1.3 ng/ml in 16-wk CCl4-treated rats after 72-h sere-
laxin infusion (4 μg/h s.c.), but serelaxin was undetectable following vehicle infusion. Serelaxin
decreased RVR compared to vehicle (29.3 ± 2.8 mm Hg/ml/min versus 46.46 ± 6.9 mm Hg/
ml/min; d = −17.18, 95% CI −33.07, −1.29; p = 0.04) (S5A Fig) and increased RBF by 54%
(3.8 ± 0.3 ml/min versus 2.5 ± 0.2 ml/min; d = 1.34, 95% CI 0.47, 2.22; p = 0.005) (Fig 3B). Fur-
thermore, serelaxin increased GFR by 371% compared to vehicle (2.6 ± 0.3 ml/min versus
0.7 ± 0.3 ml/min; d = 1.91, 95% CI 1.06, 2.76; p< 0.001) (Fig 3C), completely restoring GFR to
that of control rats. The filtration fraction (FF; GFR/RBF) increased from 0.32 ± 0.09 to
0.79 ± 0.12 (d = 0.47, 95% CI 0.12, 0.83; p = 0.015) following serelaxin treatment (S5C Fig).
However, there was no difference in MAP (serelaxin 106 ± 4 mm Hg versus vehicle 105 ± 4
mm Hg; d = 1.13, 95% CI −12.06, 14.31; p = 0.86) (Fig 3D) or serum total nitrite levels (sere-
laxin 18.6 ± 1.7 μmol/l versus vehicle 16.5 ± 2.8 μmol/l; d = 2.4, 95% CI −4.99, 9.8; p = 0.48)
(S6A Fig). The effects of serelaxin on RBF and GFR were not associated with a change in the
degree of liver injury or fibrosis (S6C and S6E Fig).
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Sustained serelaxin treatment increased renal perfusion and reversed
renal dysfunction in decompensated bile-duct-ligated cirrhotic rats
To determine whether the effects of serelaxin on RBF and GFR were dependent on model or
disease stage, we repeated all our analyses in BDL rats with decompensated cirrhosis. Mean
serum serelaxin levels were 10.6 ± 1.8 ng/ml in 3-wk BDL rats after 72-h serelaxin infusion
(4 μg/h s.c.), but serelaxin was undetectable following vehicle infusion. Serelaxin decreased
RVR compared to vehicle (35.9 ± 2.4 mm Hg/ml/min versus 53.1 ± 7.4 mm Hg/ml/min; d =
−17.2, 95% CI −32.34, −2.08; p = 0.03) (S5B Fig) and increased RBF by 53% (2.3 ± 0.2 ml/min
versus 1.5 ± 0.2 ml/min; d = 0.84, 95% CI 0.23, 1.46; p = 0.012) (Fig 3F). Moreover, serelaxin
increased GFR by 350% compared to vehicle (2.1 ± 0.5 ml/min versus 0.6 ± 0.2 ml/min; d =
1.55, 95% CI 0.45, 2.65; p = 0.011) (Fig 3G), representing an improvement to 86% of sham con-
trol levels. The FF increased from 0.25 ± 0.14 to 0.84 ± 0.11 (d = 0.58, 95% CI 0.18, 0.98; p =
0.009) following serelaxin treatment (S5D Fig). However, there were no differences in MAP
(serelaxin 81 ± 8 mm Hg versus vehicle 73 ± 4 mm Hg; d = 8.72, 95% CI −13.08, 30.51 p = 0.39)
(Fig 3H) or serum total nitrite level (serelaxin 30.7 ± 7.2 μmol/l versus vehicle 30.8 ± 4.2 μmol/l;
d = 2.51, 95% CI −15.6, 20.6; p = 0.76) (S6B Fig), and the effects of serelaxin were independent
of biliary injury and liver fibrosis (S6D and S6F Fig).
Fig 3. Effect of 72-h serelaxin infusion on renal perfusion and renovascular responses in cirrhotic rats. Relative Rxfp1
transcripts (normalized to 18S rRNA) in whole kidney extracts from 16-wk CCl4 (A) and 4-wk bile duct ligation (BDL) (E) rats (n =
3–6). Renal blood flow (RBF; B and F), mean arterial pressure (MAP; D and H), and glomerular filtration rate (GFR; C and G) in
CCl4 and BDL rats after 72-h s.c. serelaxin or vehicle (n = 5–8). Data presented as mean ± standard error of the mean (SEM),
analyzed by unpaired t-test (*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant). Concentration–response curves to
acetylcholine (ACh; I), phenylephrine (PE; J), and sodium nitroprusside (SNP; K) in the presence of serelaxin or vehicle in 16-wk
CCl4 rats (n = 5–8). Data presented as mean ± SEM, analyzed by two-way ANOVA with post hoc Bonferroni correction (*p < 0.05;
**p < 0.01; ***p < 0.001). OO, olive oil.
doi:10.1371/journal.pmed.1002248.g003
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Sustained serelaxin treatment restored endothelium-dependent
vasodilation in isolated renal arteries from CCl4 cirrhotic rats
Serelaxin treatment (4 μg/h s.c. for 72 h) restored normal endothelium-dependent vasodilation
responses in isolated extrarenal arteries, but no such effect was observed following vehicle
infusion (Fig 3I). Serelaxin had no effect on vasoconstriction or endothelium-independent
vasodilation in these arteries (Fig 3J and 3K).
Serelaxin induced renal arterial vasodilation in cirrhotic rats through
activation of the AKT/eNOS/NO signaling pathway
Serelaxin treatment (4 μg/h s.c. for 72 h) increased p-eNOS and p-AKT protein in whole
kidney in both rat cirrhosis models (Fig 4A–4F) and augmented NOS activity to levels
Fig 4. Effect of sustained serelaxin infusion on AKT/eNOS/NO signaling in cirrhotic rat kidney. Quantification
of p-eNOS/eNOS and p-AKT/AKT in whole kidney extracts from 72-h serelaxin- or vehicle-treated 16-wk CCl4 and
4-wk bile duct ligation (BDL) rats (n = 4) (A–F). Data presented as mean ± standard error of the mean (SEM),
analyzed by unpaired t-test (*p < 0.05; **p < 0.01; ***p < 0.001). NOS activity in whole kidney extracts from CCl4
(G) and BDL (H) rats treated with serelaxin or vehicle (n = 6–8). Data presented as mean ± SEM, analyzed by
unpaired t-test (*p < 0.05; **p < 0.01). Renal blood flow (RBF; I) and glomerular filtration rate (GFR; J) in 16-wk CCl4
rats co-treated with L-NG-nitroarginine methyl ester (L-NAME) (n = 4–8). Data presented as mean ± SEM, analyzed
by one-way ANOVA with post hoc Bonferroni correction (*p < 0.05; **p < 0.01; ***p < 0.001). OO, olive oil.
doi:10.1371/journal.pmed.1002248.g004
Serelaxin for renal dysfunction in cirrhosis
PLOS Medicine | DOI:10.1371/journal.pmed.1002248 February 28, 2017 15 / 29
approximating those of controls (CCl4: serelaxin 122% ± 31% of control kidney NOS activity
versus vehicle 5% ± 3%; d = 114, 95% CI 6.45, 223, p = 0.035; BDL: serelaxin 86% ± 22% versus
vehicle 26% ± 11%; d = 60, 95% CI 4.2, 115, p = 0.032) (Fig 4G and 4H). To confirm NOS
requirement, subgroups of CCl4 cirrhotic rats were co-treated with L-NAME (250 mg/l per os).
L-NAME inhibited eNOS expression and NOS activity in kidney (S7A–S7C Fig) and increased
MAP (S7D Fig), but abrogated the effects of serelaxin on RBF and GFR (Fig 4I and 4J).
Renal blood flow and oxygenation in rats with advanced cirrhosis was
augmented by a single intravenous bolus of serelaxin
The mean serum serelaxin level at 60 min after serelaxin i.v. injection (4 μg in 200 μl) was
6.0 ± 0.3 ng/ml, whereas serelaxin was undetectable after vehicle injection (200 μl). In CCl4 cir-
rhotic rats, a single i.v. serelaxin bolus increased RBF by 50% from baseline after 60 min (d =
0.66, 95% CI 0.26, 1.05; p = 0.016) (Fig 5A). Age- and sex-matched healthy control rats showed
a smaller (30%) increase from baseline in RBF at 60 min following serelaxin (d = 0.29, 95% CI
0.05, 0.53; p = 0.019) (Fig 5A). Serelaxin induced a modest increase in resting HR (S8A and
S8B Fig) but had no effect on MAP in cirrhotic rats (Fig 5B).
Fig 5. Effect of acute serelaxin treatment on renal blood flow and tissue oxygenation in CCl4 cirrhotic rats. Renal
blood flow (RBF, A) and mean arterial pressure (MAP, B) responses to acute i.v. serelaxin (4 μg) or vehicle in 16-wk CCl4
rats (n = 5–7). Measurement of velocity time integral (C) and renal resistive index (D) following acute i.v. serelaxin (4 μg) or
vehicle (n = 6–8). Deoxygenated hemoglobin levels (R2*) in renal medulla in 8-wk (E) and 16-wk (F) CCl4 rats at baseline,
30 min, and 60 min following acute i.v. serelaxin (4 μg) or vehicle (n = 5–8). Data presented as mean ± standard error of the
mean, analyzed by two-way ANOVA (*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant) with post hoc Bonferroni
correction to compare individual CCl4 time points with respective vehicle controls (#p < 0.05; ##p < 0.01; ###p < 0.001).
doi:10.1371/journal.pmed.1002248.g005
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The effects of serelaxin on RBF and CO were also measured noninvasively by ultrasound.
Over a 60-min observation period, treatment of CCl4 cirrhotic rats with serelaxin (4 μg in
200 μl) increased the renal arterial velocity time integral relative to vehicle control (d = 1.29,
95% CI 0.25, 2.32; p = 0.007) (Fig 5C), and there was a significant effect of serelaxin treatment
on renal resistive index (F[1,92] = 11.66, p = 0.001) (Fig 5D). There was no change in CO at 60
min following either serelaxin or vehicle (S8C Fig).
Additionally, serelaxin (4 μg in 200 μl) reduced levels of R2 (indicative of lower levels of
deoxygenated hemoglobin) in the renal medulla and cortex of 8-wk (early cirrhosis) and
16-wk (established cirrhosis) CCl4 rats after 60 min measured using BOLD-MRI (Figs 5E, 5F
and S8D), whereas vehicle (200 μl) had no effect.
As NO is pivotal to the mechanism of vasodilation proposed for serelaxin [25], we also
investigated the acute hemodynamic response to the NO-releasing drug SNP using doses pre-
viously shown to increase hind-limb blood flow in rats [26]. In contrast to the selective effect
of i.v. serelaxin on RBF (and PP [17]), with preservation of MAP, SNP caused a dose-depen-
dent decrease in MAP and failed to increase renal perfusion (S9 Fig).
Serelaxin exhibited systemic anti-inflammatory effects and
downregulated vasoconstrictor genes in kidney
Tumor necrosis factor α (TNFα) is a major pro-inflammatory cytokine that contributes to
endothelial dysfunction through dysregulation and uncoupling of eNOS [27]. Baseline serum
TNFα concentrations were significantly increased in both cirrhosis models (OO 20.5 ± 0.5 pg/
ml versus 16-wk CCl4 1,102 ± 270 pg/ml, d = 1,081, 95% CI 470, 1,693, p< 0.001; sham 727 ±
219 pg/ml versus BDL 4,006 ± 247 pg/ml, d = 3,279, 95% CI 1,417, 5,141, p< 0.001). Serelaxin
infusion for 72 h (4 μg/h s.c.) reduced serum TNFα levels (CCl4: serelaxin 94.7 ± 61 pg/ml ver-
sus vehicle 817.3 ± 151 pg/ml, d = −722, 95% CI −1,400, −45.2, p = 0.033; BDL: serelaxin
1,516 ± 549 pg/ml versus 3,933 ± 391 pg/ml, d = −2,417, 95% CI −4,005, −828, p = 0.0014)
(S10A and S10B Fig). Serelaxin also decreased transcripts for Ednra, urotensin-II receptor
(Uts2r), and urotensin-II (Uts2) in the kidneys of cirrhotic rats (S10C Fig).
Results of an exploratory phase 2 study of serelaxin in patients with
compensated cirrhosis and portal hypertension
Based upon the positive results of serelaxin treatment in experimental models, we proceeded
to a human study that consisted of two parts: Part A and Part B. Here we present the data from
Part A. A total of 41 male and female participants with compensated alcohol-related cirrhosis
and PHT were randomized, and 40 went on to receive serelaxin or terlipressin treatment in a
1:1 ratio (Fig 6). Of these, 38 participants (19 in each treatment group) completed the study.
Two participants (one from each group) did not return for the end of study visit but were con-
firmed to be alive at 90 d after their scheduled end of study visit. The main demographic and
clinical characteristics of the study participants are shown in Table 1. Baseline data were gener-
ally comparable between the two treatment arms. A summary of the hemodynamic data from
the study is presented in S1 Table.
Dynamic blood flow measurements by PC-MRA. The primary outcome of the study was
the change in total renal arterial blood flow measured by PC-MRA after 120 min of serelaxin
infusion. Serelaxin infusion caused a substantial increase (+65%, 95% CI 40%, 95%) from base-
line in total renal arterial blood flow (0.63 l/min, 95% CI 0.49, 0.81, versus 1.04 l/min, 95% CI
0.85, 1.28; p< 0.001), associated with a decrease in RVR (from 171 mm Hg/l/min, 95% CI 133,
219, to 100 mm Hg/l/min, 95% CI 83, 121; p< 0.001) (Fig 7A and 7G). There were only mod-
est effects of serelaxin on secondary outcomes, including an increase in blood flow from
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baseline in the superior abdominal aorta (+8%, 95% CI 2%, 14%; p = 0.017) and nonsignificant
changes in hepatic artery flow (+18%, 95% CI −3%, 44%; p = 0.11) and portal vein flow (−12%,
95% CI −22%, 0%; p = 0.11) (Fig 7; S1 Table). Notably, there was no change in blood flow from
baseline in the SMA (Fig 7C) or in total liver blood flow (S1 Table).
Administration of a single 2-mg i.v. bolus of terlipressin caused no significant change from
baseline in RVR or total renal arterial blood flow after 120 min (+14%, 95% CI −3%, 33%;
p = 0.25). However, there was a substantial decrease in SMA flow (−37%, 95% CI −45%, −28%;
p< 0.001), portal vein flow (−40%, 95% CI −57%, −16%; p = 0.01), azygos blood flow (−30%,
95% CI −41%, −18%; p< 0.001), and total liver blood flow (−35%, 95% CI −51%, −13%; p =
0.015) (Fig 7; S1 Table).
Although this study was not powered for comparison between serelaxin and terlipressin, the
change from baseline blood flow in several vessels was significantly different between the treat-
ment arms (S2 Table). Notably, the increase in total renal arterial blood flow was much greater
following serelaxin compared with terlipressin (d = 0.35 ± 0.10, 95% CI 0.15, 0.54; p = 0.001).
Fig 6. Flow chart of participants in the study.
doi:10.1371/journal.pmed.1002248.g006
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Safety and tolerability assessments. Overall, serelaxin was well tolerated. A total of three
patients (15%) in the serelaxin group and 11 patients (55%) in the terlipressin group developed
at least one AE (Table 2). AEs associated with terlipressin (mainly gastrointestinal) were consis-
tent with the product label. There were no deaths reported during treatment or the protocol-
specified 4-wk follow-up period. No meaningful changes in liver function tests were associated
with serelaxin treatment. There was no significant change in MAP from baseline following 120
min of serelaxin infusion (108 mm Hg, 95% CI 101, 115, versus 105 mm Hg, 95% CI 98, 111; p
= 0.5002; Fig 7F; S1 Table), and no AEs of hypotension or any discontinuations due to a blood
pressure decrease. Electrocardiographic data were evaluated by an independent vendor (ERT)
and demonstrated that there was no relevant effect of serelaxin on cardiac repolarization or
other electrocardiographic effects. One participant in each group experienced a treatment-
emergent SAE during the study (serelaxin: vomiting and ascites; terlipressin: alcohol poisoning,
fall, and noncardiac chest pain). In both cases, alcohol intoxication provided an explanation for
these SAEs, and a certain causal relationship could not be established.
Pharmacokinetic, immunogenicity, and biomarker evaluations in serelaxin-treated
patients. No dose adjustments or interruptions of treatment were made in the study. Serum
serelaxin concentration (Fig 8A) increased rapidly to 14.6 ng/ml (range 9.5, 23.2) following the
initial 60-min fast infusion rate (80 μg/kg/d), then decreased to 12.2 ng/ml (range 8.1, 17.9) fol-
lowing the subsequent slower infusion rate (30 μg/kg/d), and declined rapidly to 6.1 ng/ml
(range 4.4, 9.9) during the recovery phase (~60 min following cessation of serelaxin). Serelaxin
was undetectable at week 4 of the study. No patients had detectable anti-serelaxin antibodies at
baseline or at 4 wk post-treatment. There were no significant changes from baseline observed
in levels of prespecified peripheral plasma biomarkers following serelaxin exposure (Fig 8B–
8D; nitrate 11.6 pmol/l, 95% CI 8.5, 15.9, versus 12.0 pmol/l, 95% CI 8.6, 16.7; ET-1 2.8 pmol/l,
95% CI 1.8, 4.2, versus 2.7 pmol/l, 95% CI 1.7, 4.2; MMP-9 53.1 μg/l, 95% CI 46.3, 60.9, versus
44.8 μg/l, 95% CI 39.5, 50.7).
Table 1. Baseline demographic and clinical characteristics of study participants at screening.
Characteristic Serelaxin (n = 20) Terlipressin (n = 20)
Sex, n (percent) male/female 16 (80%)/4 (20%) 16 (80%)/4 (20%)
Age (years)* 60 (57, 64) 55 (51, 58)
Body mass index (kg/m2)* 30 (28, 32) 28 (25, 31)
Alcohol use, n (percent) A/L/O† 13 (65%)/7 (35%)/0 10 (50%)/4 (20%)/6 (30%)
Albumin (g/l)* 40 (37, 43) 41 (39, 42)
Bilirubin (μmol/l)* 12 (8, 18) 19 (12, 29)
INR* 1.2 (1.1, 1.3) 1.2 (1.1, 1.3)
Creatinine (μmol/l)* 73 (66, 81) 66 (59, 73)
eGFR (ml/min/1.73 m2)* 90 (78, 103) 104 (89, 120)
Platelet count (× 10−3)* 77 (42, 143) 95 (68, 134)
Mean arterial pressure (mm Hg)* 108 (101, 115) 105 (98, 112)
Heart rate (beats/min)* 71 (67, 75) 65 (61, 70)
Child-Pugh score* 5 (5, 6) 5 (5, 6)
MELD score* 9 (8, 10) 10 (8, 11)
Previous variceal bleed, n (percent) 7 (35%) 3 (15%)
Splenomegaly, n (percent) 13 (65%) 15 (75%)
*Data expressed as mean (95% CI), except mean arterial pressure and heart rate, which are expressed as geometric mean ± 95% CI.
†A = abstinent, L = less than one drink per day, O = one to two drinks per day.
eGFR, estimated glomerular filtration rate; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease.
doi:10.1371/journal.pmed.1002248.t001
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Discussion
We have shown for the first time, to the best of our knowledge, that serelaxin attenuated renal
vasoconstriction (RVR), improved RBF and endothelial dysfunction, and reversed impaired
kidney function in experimental rat models of cirrhosis, PHT, and renal dysfunction (Fig 3).
Crucially, we went on to demonstrate the translational relevance of these findings by showing
in patients with cirrhosis and PHT that serelaxin reduced RVR and caused a substantial
increase in RBF (Fig 7).
Fig 7. Differential effects of serelaxin and terlipressin treatment on splanchnic and extra-splanchnic
hemodynamics. Blood flow changes in total renal artery (left + right renal artery; A), superior abdominal aorta
(B), superior mesenteric artery (C), portal vein (D), and hepatic artery (E); mean arterial pressure (MAP; F);
and renal vascular resistance (G) following serelaxin infusion (60 min at 80 μg/kg/d then 60 min at 30 μg/kg/d)
or terlipressin (2-mg i.v. bolus). Data presented as geometric mean ± 95% CI, analyzed by paired t-tests for
within-group comparison of baseline and post-treatment flow measurements (n = 20; *p < 0.05; ***p < 0.001;
NS, not significant).
doi:10.1371/journal.pmed.1002248.g007
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In two pathologically distinct rat models, advancement of cirrhosis was associated with a
progressive reduction in RBF and GFR (Fig 1). The beneficial effects of serelaxin on RBF and
GFR were dependent on an increase in renal NO signaling (as the effect was abrogated by co-
treatment with L-NAME; Fig 4) and were associated with downregulation of vasoconstrictor
receptor expression in cirrhotic rat kidney (S10 Fig). In contrast, administration of a nonselec-
tive nitrovasodilator induced hypotension and reduced RBF (S9 Fig), consistent with previous
observations in human cirrhosis [28].
Both acute (i.v. bolus; Fig 5) and sustained (72-h s.c. infusion; Fig 3) serelaxin treatment
induced a significant increase in RBF in cirrhotic rats. However, the relative effect of serelaxin
on GFR was even greater (Fig 3). In both models the GFR was restored to near-normal levels
and the FF increased (S5 Fig), suggesting a differential effect on afferent and efferent renal
arteriolar tone. This is a significant observation because an increase in RBF by other renal
vasodilators, such as dopamine, is not necessarily accompanied by an increase in GFR [29].
Additionally, serelaxin may augment renal function by modifying other nonvasomotor fac-
tors, such as inflammation, that also contribute to renal dysfunction in cirrhosis [30]. Indeed,
previous studies have demonstrated that serelaxin is a vasoprotective molecule under condi-
tions of acute inflammation/oxidative stress (reviewed in [31]). In our preclinical cirrhosis
models, serelaxin decreased the (elevated) serum levels of TNFα (S10 Fig), a pro-inflammatory
cytokine heavily implicated in endothelial dysfunction. Moreover, co-incubation of TNFα-
exposed aortic rings with serelaxin was shown to increase eNOS activity, attenuate arginase-II
expression, and improve vasorelaxation [31]. Both large and small renal arteries isolated from
Table 2. Overview of safety data.
Adverse event Serelaxin (n = 20) Terlipressin (n = 20)
Any AE 3 (15%) 11 (55%)
Suspected treatment-related AE 1 (5%) 10 (50%)
Any SAE 1 (5%) 1 (5%)
Suspected treatment-related SAE 0 0
Death up to 30 d 0 0
Dose interruption 0 0
Treatment withdrawal 0 0
AE regardless of study drug relationship
Abdominal pain 0 4 (20%)
Alcohol poisoning 0 1 (5%)
Ascites 1 (5%) 0
Cellulitis 1 (5%) 0
Diarrhea 0 6 (30%)
Electrocardiogram QT prolonged 1 (5%) 1 (5%)
Fall 0 1 (5%)
Headache 0 1 (5%)
Hypertension 0 3 (15%)
Noncardiac chest pain 0 1 (5%)
Pruritus 1 (5%) 0
Syncope 0 1 (5%)
Vomiting 1 (5%) 1 (5%)
Data given as n (percent). Adverse events (AEs) and serious adverse events (SAEs) are shown, regardless of study drug relationship, by preferred term
and treatment group.
QT, QT interval.
doi:10.1371/journal.pmed.1002248.t002
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CCl4 and BDL cirrhotic rats exhibited marked impairment in endothelium-dependent vasodi-
lation (Fig 2), consistent with a study in human cirrhosis linking endothelial dysfunction with
the development of renal vasoconstriction and renal failure [32]. However, 72-h serelaxin infu-
sion restored renovascular function (Fig 3) and decreased RVR (S5 Fig). Taken together, our
findings indicate that serelaxin, through a number of mechanisms, modulated renal arterial
endothelial responsiveness in cirrhosis in favor of vasodilatation.
Notably, serelaxin treatment also decreased transcription of the vasoconstriction-related
genes Ednra and Uts2r in cirrhotic rat kidneys (S10 Fig). Endothelin receptor A is a smooth
muscle receptor that mediates increased vascular tone after stimulation by endothelin-I
whereas urotensin-II is a potent vasoconstrictor of large conductive vessels but, paradoxically,
relaxes mesenteric vessels. Circulating levels of urotensin-II are elevated in human cirrhosis,
and a urotensin-II receptor antagonist reduced PP and increased RBF in BDL rats [33].
The levels of transcripts for the cognate receptor for human relaxin-2 (Rxfp1) were
increased in whole kidney and renal artery extracts in cirrhotic rats (Fig 3). Furthermore,
RXFP1 protein localized to renal vessels (endothelium and smooth muscle) and perivascular
adventitial cells in both rat and human kidney (S4 Fig). Investigation of differential expression
of RXFP1 and relative dilator sensitivity to serelaxin in the afferent and efferent renal arterioles
(e.g., by videomicroscopy) is an interesting topic for future study. Moreover, the factors that
regulate renal parenchymal and arterial expression of RXFP1 in animal models and human
disease are unknown, although a recent study showed that α1- and β1-adrenoceptors regulated
cardiac expression of RXFP1 in mice [34].
Fig 8. Effect of serelaxin infusion on pharmacokinetics and plasma biomarkers in patients with
cirrhosis and portal hypertension. Serum serelaxin concentration measured by ELISA pre-dose (0 min), at
60 min and 120 min post-initiation of serelaxin infusion, in recovery period (~60 min after cessation of
serelaxin), and at 4-wk follow-up visit (A). Data presented as mean ± standard deviation (n = 20). Plasma
nitrate (B), endothelin-1 (ET-1) (C), and matrix metalloproteinase-9 (MMP-9) (D) measured by ELISA pre-
dose (0 min) and at 120 min after initiation of serelaxin infusion. Data presented as geometric mean ± 95% CI
(n = 20). NS, not significant.
doi:10.1371/journal.pmed.1002248.g008
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Encouraged by preclinical studies, we undertook an exploratory trial in patients with com-
pensated cirrhosis and PHT. The hemodynamic changes induced by terlipressin were consis-
tent with its known activity as a potent splanchnic and systemic vasoconstrictor and validated
the use of PC-MRA in this population (Fig 7; S1 Table). Infusion of serelaxin for 120 min
achieved similar steady-state serum concentrations to those observed in our 72-h rat cirrhosis
models and in human heart failure following 48-h i.v. infusion [21]. Baseline RBF levels in our
cirrhosis population were lower than that reported in a large series of healthy volunteers
(0.838 ± 0.244 l/min), measured using PC-MRA [35]. Serelaxin treatment elicited a selective,
highly significant, and clinically relevant increase in total RBF that was associated with a sub-
stantial reduction in RVR but only a small increase in superior aortic flow, as a surrogate of
increased CO (Fig 7). Effects on key secondary outcomes included a nonsignificant decrease in
portal venous flow (Fig 7), but, importantly, total hepatic blood flow was preserved (S1 Table)
—in contrast to splanchnic vasoconstrictors such as terlipressin that further compromise
hepatic perfusion in cirrhosis and may impair organ function. Additionally, there was no
increase in SMA flow or azygos flow and, critically, no detrimental effects on blood pressure or
increase in circulating NO levels (Fig 8). Interestingly, our demonstration of differential vis-
ceral blood flow responses in cirrhotic patients using MRI are consistent with the preclinical
literature, which has revealed that serelaxin preferentially dilates constricted vessels and exerts
quite heterogeneous responses across distinct regions of the vasculature [36,37].
There are limitations to our study that merit discussion. It should be acknowledged that
there is no ideal animal model of renal dysfunction in cirrhosis (especially HRS), and therefore
one must be cautious regarding the generalizability of preclinical observations. However, our
findings in CCl4 and BDL rats corroborate clinical data showing that advancement of hepatic
fibrosis is associated with progressive renal vasoconstriction and functional impairment—seen
at its most extreme in HRS [10,38,39]. Moreover, BDL is considered a suitable model of
human HRS [40] and was recently shown to share innate immune defects and clinical charac-
teristics with acutely decompensated cirrhosis in patients [41]. Although we and others [42]
observed features of ATN in rat BDL kidneys, emerging histological and biomarker studies
indicate that tubular injuries are frequently present in cirrhotic patients with renal dysfunction
[43,44]. The primary objectives of our clinical study were to define the hemodynamic effects
and safety profile of serelaxin in patients with cirrhosis and PHT. Although this exploratory
trial was (necessarily) open-label, we ensured that outcome assessors were blinded to treat-
ment allocation to avoid potential bias. Additionally, MRA scans were reanalyzed by an inde-
pendent clinical research organization using a fully automated approach to completely
eliminate possible reader bias; automated and semi-automated data were highly correlated. It
should also be noted that the study population consisted of patients with well-compensated
cirrhosis and PHT, but without significant impairment of renal function. Further studies are
now required in patients with more advanced cirrhosis and renal dysfunction to link the sub-
stantial increase in RBF we observed with serelaxin to improvements in renal function and
patient outcomes. Recent clinical data provide encouragement in this regard. First, the phar-
macokinetic and safety profiles of serelaxin were not affected in patients with mild, moderate,
and severe hepatic impairment [45]. Second, serelaxin had a beneficial effect on renal bio-
markers (creatinine and cystatin C) and survival in patients with acute heart failure [46].
In summary, our mechanistic findings in rat models and exploratory study in human
cirrhosis suggest a potential therapeutic role for serelaxin in the treatment of renal dysfunc-
tion in cirrhosis and possibly other human conditions where RBF or endothelial function is
compromised.
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S1 Fig. Characterization of rat cirrhosis models. (A) Representative rat liver stained with
hematoxylin and eosin (H&E) and picrosirius red (PSR) (scale bar 200 μm) in 8- and 16-wk
olive oil (OO)-treated and CCl4-treated rats (n = 6–12) showing necroinflammation (arrow-
heads) and accumulation of fibrillar collagen (arrows). (B) Collagen proportionate area (CPA,
percent) calculated by morphometric analysis of PSR staining. (C) Alanine aminotransferase
(ALT) (one-way ANOVA: F[2,19] = 3.78; p = 0.042) and (D) albumin levels quantified in
serum (one-way ANOVA: F[2,17] = 3.8; p = 0.043). (E) Representative H&E- and PSR-stained
rat liver (scale bar 200 μm) showing necroinflammation (arrowheads) and deposition of fibril-
lar collagen (arrows) after bile duct ligation (BDL) (n = 5–6). (F) CPA, (G) serum alkaline
phosphatase (ALP), and (H) albumin levels. (I) Acute tubular necrosis (ATN) score in BDL rat
kidney. Data presented as mean ± standard error of the mean, analyzed by one-way ANOVA
with post hoc Bonferroni correction (p< 0.05; p< 0.01; p< 0.001; NS, not significant).
(PDF)
S2 Fig. Renal vascular endothelial function in rat cirrhosis models. Concentration–response
curves to acetylcholine (ACh; 10−9 to 10−5 M) in isolated segmental (A) and interlobar (B)
renal arteries from 16-wk CCl4 and olive oil (OO) rats (n = 8–12) and in segmental (C) and
interlobar (D) arteries from 4-wk bile duct ligation (BDL) and sham rats. Concentration–
response curves to ACh (10−9 to 10−5 M) in extrarenal renal arteries from 16-wk OO (E) and
CCl4 (F) rats co-treated with L-N
G-nitroarginine methyl ester (L-NAME) (1 × 10−4 M), indo-
methacin (1 × 10−5 M), or apamin (1 × 10−4 apamin M) plus charybdotoxin (1 × 10−5 M). Data
expressed as mean ± standard error of the mean, analyzed by two-way ANOVA with post hoc
Bonferroni correction (p< 0.05; p< 0.01; p< 0.001).
(PDF)
S3 Fig. Regulation of vasomotor factors in rat cirrhosis models. Quantification of relative p-
eNOS/eNOS protein expression in whole kidney extracts from 16-wk CCl4 (A) and 4-wk bile
duct ligation (BDL) (B) rat kidney (n = 4). Fold regulation of mRNA transcripts for vasoregu-
latory genes in kidney tissue from 16-wk CCl4 rats compared to olive oil (OO) rats (C) and
BDL rats compared to sham rats (D) (n = 3–6). Genes with fold regulation >2 with p< 0.05
are presented (arginase-II, Arg2; caveolin-I, Cav1; endothelin receptor A, Ednra; endothelin
receptor B, Ednrb). Quantification of arginase-II protein (E and F) and caveolin-I (G and H)
relative to GAPDH in 16-wk CCl4 and 4-wk BDL rat kidney compared to controls. Data
expressed as mean ± standard error of the mean, analyzed by unpaired two-tailed t-test (p<
0.05; p< 0.01; p< 0.001; NS, not significant).
(PDF)
S4 Fig. Expression and distribution of RXFP1 in cirrhotic rat and normal human kidney.
Relative Rxfp1 transcript level (normalized to 18S rRNA) in renal artery extracts from 16-wk
CCl4 (A; p = 0.059) and 4-wk bile duct ligation (BDL) (C; p = 0.067) rats (n = 3–6). Quantifica-
tion of RXFP1 protein relative to GAPDH in whole kidney from 16-wk olive oil (OO) and
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CCl4 (B) and 4-wk sham and BDL (D) rats (n = 4). Data expressed as mean ± standard error of
the mean, analyzed by unpaired two-tailed t-test (p< 0.05). Representative immunofluores-
cence staining for RXFP1 (and isotype control) in 16-wk OO and CCl4 kidney, in 4-wk sham
and BDL kidney (E), and in biopsy tissue from normal human kidney (F). DAPI nuclear coun-
terstain (size bars 100 μm).
(PDF)
S5 Fig. Effect of 72-h serelaxin infusion on renal vascular resistance and filtration fraction
in cirrhotic rats. Renal vascular resistance (RVR; A and B) and filtration fraction (FF; C and
D) in CCl4 and bile duct ligation (BDL) rats after 72-h subcutaneous serelaxin or vehicle (n =
5–8). Data presented as mean ± standard error of the mean, analyzed by unpaired t-test (p<
0.05; p< 0.01; p< 0.001; NS, not significant).
(PDF)
S6 Fig. Effect of 72-h serelaxin infusion on serum and tissue markers in rat cirrhosis mod-
els. Serum total nitrite levels in 16-wk CCl4 (A) and 4-wk bile duct ligation (BDL) (B) rats after
72-h subcutaneous serelaxin or vehicle infusion. Serum alanine aminotransferase (ALT) levels
in 16-wk CCl4 rats (C) and alkaline phosphatase (ALP) levels in 4-wk BDL (D) rats. Data
expressed as mean ± standard error of the mean (SEM) (n = 6–8), analyzed by unpaired two-
tailed t-test (NS, not significant). Collagen proportionate area (CPA, percent) measured by
morphometric analysis of picrosirius-red-stained liver sections in 16-wk CCl4 (E) and 4-wk
BDL (F) rats (n = 4). Data expressed as mean ± SEM, analyzed by unpaired two-tailed t-test.
(PDF)
S7 Fig. Effect of L-NG-nitroarginine methyl ester administration on nitric oxide bioavail-
ability and mean arterial pressure in serelaxin-treated CCl4 rats. Quantification of eNOS
protein (relative to GAPDH loading control) in whole kidney extracts from subgroups of
16-wk CCl4 rats randomized to treatment with serelaxin ± L-NG-nitroarginine methyl ester
(L-NAME) (A) or vehicle ± L-NAME (B) (n = 4). Data expressed as mean ± standard error
of the mean (SEM), analyzed by unpaired two-tailed t-test (p< 0.05; p< 0.001) (C).
Nitric oxide synthase (NOS) activity in whole kidney extracts (n = 4–8). Mean arterial pres-
sure (MAP) response (D) (n = 4–8). Data expressed as mean ± SEM, analyzed by one-way
ANOVA with post hoc Bonferroni correction (p< 0.05; p< 0.01; p< 0.001; NS, not
significant).
(PDF)
S8 Fig. Hemodynamic effects of acute serelaxin treatment in CCl4 cirrhotic rats. Heart rate
(HR; beats per min, bpm) measured in 16-wk CCl4 rats (n = 7) randomized to intravenous
(i.v.) serelaxin (4 μg in 200 μl, A) or vehicle (200 μl, B) for 60 min by femoral artery catheter.
Cardiac output by M-mode Doppler (C) (n = 6–9). HR data presented as individual rats at
each time point; CO data plotted at baseline and 60 min for individual rats. HR data analyzed
using one-way ANOVA and CO data by two-way ANOVA, both with post hoc Bonferroni
correction (p< 0.001; NS, not significant). Deoxygenated hemoglobin levels (R2) in renal
cortex measured by blood-oxygen-level-dependent MRI in 8-wk CCl4-treated rats (n = 7) at
baseline and 30 min and 60 min following i.v. serelaxin (4 μg in 200 μl) or vehicle (200 μl) (D).
Data expressed as mean ± standard error of the mean, analyzed by two-way ANOVA with post
hoc Bonferroni correction (p< 0.05).
(PDF)
S9 Fig. Hemodynamic effects of a classical nitrovasodilator in CCl4 cirrhotic rats. Effect of
acute intravenous boluses of sodium nitroprusside (SNP; dose range 0.09–9 μg) on mean
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arterial pressure (MAP; A) in 16-wk CCl4 rats at serial time points, and the percentage change
in renal blood flow (RBF) from baseline (B) over a 10-min observation period (n = 6). Data
expressed as mean ± standard error of the mean (SEM), analyzed by one-way ANOVA with
post hoc Bonferroni correction. Dose–response effect of SNP at baseline compared to 10-min
MAP (C) and RBF (D). Data points represent mean ± SEM, analyzed by paired two-tailed t-
test (p< 0.05).
(PDF)
S10 Fig. Effect of 72-h serelaxin infusion on serum TNFα and renal vasoconstrictor gene
expression. Serum TNFα levels measured by ELISA in 4-wk sham and bile duct ligation
(BDL) (A) and 16-wk olive oil (OO) and CCl4 (B) rats treated for 72 h with subcutaneous sere-
laxin or vehicle (n = 5–8). Data presented as individual values with mean ± standard error of
the mean, analyzed by one-way ANOVA with post hoc Bonferroni correction (p< 0.05; p<
0.01; p< 0.001). Fold regulation of mRNA transcripts for vasoregulatory genes in kidney
tissue from 16-wk CCl4 rats compared to OO rats (n = 5) (C). Genes with a fold regulation of
>2 and significance of p< 0.05 are presented.
(PDF)
S11 Fig. Magnetic resonance angiography. (A) Position of hepatic artery flow measurement
(taken from 3-D magnetic resonance reconstruction of arterial system). (B) Phase contrast
velocity-encoded images acquired from selected vessels were analyzed for peak and average
flow over the cardiac cycle.
(PDF)
S1 Table. Summary of hemodynamic effects of serelaxin and terlipressin in patients with
cirrhosis and portal hypertension. Total renal artery flow = left + right renal artery flow; total
liver flow = hepatic artery + portal vein flow. Renal vascular resistance = mean arterial pres-
sure/total renal arterial blood flow.
(DOCX)
S2 Table. Comparative analysis of the change in blood flow from baseline in response to
serelaxin and terlipressin treatment. An unpaired t-test was used to compare the difference
in blood flow change from baseline induced by serelaxin and terlipressin in prespecified ves-
sels. Mean differences, 95% CIs, and p-values are presented in the table.
(DOCX)
S1 Text. Clinical trial protocol.
(PDF)
S2 Text. CONSORT checklist.
(DOC)
S3 Text. NC3Rs ARRIVE checklist.
(PDF)
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